Valiant Labs Q3 FY26: Revenue nearly doubles YoY, but consolidated PAT swings to loss

Revenue growth above 20%Net loss reportedEBITDA margin compressionResults View source PDF Explain this filing

VALIANTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.8%Reaction day

₹65.61

prior close

₹67.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-4.3% vs market

On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

-3.3

15m

-4.5

30m

-5.1

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-4.8-0.5-4.3

Next day

-6.7-2.0-4.7

-6.6-2.7-4.0

-10.0-1.7-8.2

-9.9-1.4-8.5

-8.7-2.8-5.9

-9.9-2.8-7.1

15d

-19.8-8.4-11.3

-18.4-9.1-9.3

-10.2-4.0-6.1

+21.9+2.6+19.3

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Valiant Laboratories reported audited Q3 FY26 results. Standalone revenue rose 55% YoY to Rs 5,474 lakhs; 9M revenue doubled to Rs 15,174 lakhs. However, standalone Q3 net profit fell sharply to Rs 3.30 lakhs from Rs 160 lakhs YoY. Consolidated results swung to a loss of Rs 706 lakhs in Q3 (versus Rs 239 lakh profit YoY), mainly due to subsidiary Valiant Advanced Sciences posting heavy losses. Margins compressed significantly.

Likely market impact

Strong revenue growth but sharp drop in profitability and consolidated loss may pressure the stock near-term.